0.3011

0.63% -0.0019

Bluebird Bio Inc (BLUE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BLUE Giù? Forum Previsione

Precedente Chiudi:

$0.303

Aprire:

$0.31

Volume 24 ore:

3.16M

Relative Volume:

0.50

Capitalizzazione di mercato:

$75.10M

Reddito:

$21.73M

Utile/perdita netta:

$-91.17M

Rapporto P/E:

-0.2952

EPS:

-1.02

Flusso di cassa netto:

$-286.43M

1 W Prestazione:

-16.96%

1M Prestazione:

-39.39%

6M Prestazione:

-69.79%

1 anno Prestazione:

-91.77%

Intervallo 1D:

$0.29

$0.3139

Intervallo di 1 settimana:

$0.29

$0.3699

Portata 52W:

$0.29

$5.53

Bluebird Bio Inc Stock (BLUE) Company Profile

Nome

Bluebird Bio Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

339-499-9300

Indirizzo

455 GRAND UNION BOULEVARD, SOMERVILLE, MA

Dipendente

Cinguettio

@bluebirdbio

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

BLUE's Discussions on Twitter

Confronta BLUE con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BLUE	0.3011	75.10M	21.73M	-91.17M	-286.43M	-1.02
VRTX	449.83	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	746.11	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	594.70	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	245.75	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	107.87	24.89B	3.30B	-501.07M	1.03B	11.54

Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-04-28	Iniziato	JP Morgan	Overweight
2023-03-07	Iniziato	Robert W. Baird	Outperform
2022-08-05	Aggiornamento	Barclays	Underweight → Equal Weight
2022-08-02	Aggiornamento	Raymond James	Mkt Perform → Outperform
2022-04-06	Downgrade	Cowen	Outperform → Market Perform
2022-03-07	Downgrade	Barclays	Equal Weight → Underweight
2021-11-08	Reiterato	Barclays	Equal Weight
2021-11-08	Reiterato	Canaccord Genuity	Hold
2021-11-08	Downgrade	Goldman	Neutral → Sell
2021-11-08	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2021-11-08	Reiterato	RBC Capital Mkts	Sector Perform
2021-11-08	Reiterato	Wedbush	Neutral
2021-11-08	Reiterato	Wells Fargo	Equal Weight
2021-08-10	Downgrade	Canaccord Genuity	Buy → Hold
2021-08-10	Downgrade	Goldman	Buy → Neutral
2021-08-10	Downgrade	Wells Fargo	Overweight → Equal Weight
2021-08-10	Ripresa	William Blair	Mkt Perform
2021-08-09	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-07-01	Downgrade	Berenberg	Buy → Hold
2021-03-10	Aggiornamento	Mizuho	Neutral → Buy
2021-02-17	Downgrade	JP Morgan	Overweight → Neutral
2021-02-16	Downgrade	BofA Securities	Buy → Neutral
2021-02-16	Downgrade	Wedbush	Outperform → Neutral
2021-02-16	Downgrade	William Blair	Outperform → Mkt Perform
2020-12-09	Downgrade	Maxim Group	Buy → Hold
2020-11-11	Iniziato	Berenberg	Buy
2020-11-05	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-11-05	Downgrade	Barclays	Overweight → Equal Weight
2020-11-05	Downgrade	Stifel	Buy → Hold
2020-11-02	Aggiornamento	William Blair	Mkt Perform → Outperform
2020-10-20	Iniziato	Mizuho	Buy
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-03-27	Aggiornamento	Stifel	Hold → Buy
2020-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
2020-02-03	Ripresa	BofA/Merrill	Buy
2020-02-03	Aggiornamento	Evercore ISI	In-line → Outperform
2019-12-13	Aggiornamento	Oppenheimer	Perform → Outperform
2019-11-26	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-11-19	Downgrade	Evercore ISI	Outperform → In-line
2019-11-04	Aggiornamento	Wedbush	Neutral → Outperform
2019-10-01	Iniziato	Stifel	Hold
2019-08-12	Downgrade	William Blair	Outperform → Mkt Perform
2019-06-18	Aggiornamento	Maxim Group	Hold → Buy

Mostra tutto

Bluebird Bio Inc Borsa (BLUE) Ultime notizie

09:31 AM

Bluebird Bio's SWOT analysis: gene therapy firm faces cash crunch amid launch - Investing.com

09:31 AM

Nov 20, 2024

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024

Nov 18, 2024

Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace

Nov 18, 2024

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN

Nov 15, 2024

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL

Nov 15, 2024

Royal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE) - MarketBeat

Nov 15, 2024

bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN

Nov 15, 2024

bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors USA

Nov 15, 2024

bluebird bio stock cut at BofA and J.P. Morgan (BLUE:NASDAQ) - Seeking Alpha

Nov 15, 2024

Bluebird bio stock plunges to 52-week low of $0.34 By Investing.com - Investing.com Canada

Nov 15, 2024

bluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at Barclays - MarketBeat

Nov 15, 2024

Bluebird bio stock plunges to 52-week low of $0.34 - Investing.com

Nov 15, 2024

bluebird bio (NASDAQ:BLUE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat

Nov 15, 2024

JPMorgan Chase & Co. Downgrades bluebird bio (NASDAQ:BLUE) to Underweight - MarketBeat

Nov 15, 2024

bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors - Simply Wall St

Nov 15, 2024

Bluebird: Q3 Earnings Snapshot - Darien Times

Nov 15, 2024